|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.810 USD | -2.09% |
|
+3.31% | +9.77% |
| 07-04 | UK Regulator OKs ImmunityBio's Bladder Cancer Treatment for New Indication | MT |
| 06-02 | ImmunityBio Receives Expanded FDA Authorization to Treat Lymphopenia in Cancer Patients | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales growth | Profitability (Composite) | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
| 2.48B | - | - | - | |||
| 34.39B | ||||||
| 27.8B | - | |||||
| 30.84B | ||||||
| 18.57B | - | - | - | - | - | |
| 18.65B | - |
- Stock Market
- Equities
- IBRX Stock
- Charts ImmunityBio, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition